MARKET

TCON

TCON

Tracon Pharmaceu
NASDAQ
1.490
-0.030
-1.97%
After Hours: 1.480 -0.01 -0.67% 18:54 05/24 EDT
OPEN
1.530
PREV CLOSE
1.520
HIGH
1.540
LOW
1.482
VOLUME
56.47K
TURNOVER
0
52 WEEK HIGH
14.75
52 WEEK LOW
1.411
MARKET CAP
3.99M
P/E (TTM)
2.289
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at TCON last week (0520-0524)?
Weekly Report · 12h ago
Weekly Report: what happened at TCON last week (0513-0517)?
Weekly Report · 05/20 09:42
12 Health Care Stocks Moving In Wednesday's Intraday Session
SINTX Techs stock moved upwards by to $ during Wednesday's regular session. The company's, Q1 earnings came out 2 days ago. SINTX techs is one of a number of stocks to gain in the last few days. The stock market cap of the company stands at $ million.
Benzinga · 05/15 16:31
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
SINTX Techs stock moved upwards by to $ during Wednesday's pre-market session. The company's market cap stands at $ million. Arcutis Biotherapeutics (NASDAQ:ARQT) and MultiPlan (NYSE:MPLN) also gained.
Benzinga · 05/15 12:06
TRACON Pharmaceuticals, Inc. Form 10-Q for the Quarterly Period Ended March 31, 2024
Press release · 05/15 02:44
TCON Stock Earnings: TRACON Pharma Misses EPS for Q1 2024
TRACON Pharma (NASDAQ:TCON) reported results for the first quarter of 2024. The company reported earnings per share of -$ and revenue of $100,000. This was below the analyst estimate for EPS of - $ in the quarter.
Investorplace · 05/15 00:56
TRACON Pharma Q1 EPS $(1.33) Misses $(1.19) Estimate, Sales $100.00K
Benzinga · 05/14 20:06
*Tracon Pharma: Final Response Assessment Data in All Patients From ENVASARC Phase 2 Pivotal Trial Expected in 3Q
Dow Jones · 05/14 20:06
More
About TCON
TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its contract research organization (CRO) independent product development platform to partner with other life science companies to develop and commercialize products in the United States. The Company’s clinical-stage oncology product candidate is TRC102, which is a small molecule that has been studied in Phase 1 and Phase 2 trials for the treatment of mesothelioma, lung cancer, glioblastoma and solid tumors and YH001, which is a monospecific investigational cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody. TRC102 is a small molecule in clinical development to reverse resistance to specific chemotherapeutics by inhibiting DNA base excision repair (BER). Its clinical-stage product candidate, Envafolimab, is a PD-L1 antibody that is being developed for the treatment of sarcoma.

Webull offers TRACON Pharmaceuticals Inc stock information, including NASDAQ: TCON real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TCON stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TCON stock methods without spending real money on the virtual paper trading platform.